Search Results - "Bartlett, Derek W"

Inhibition of immune checkpoints PD-1, CTLA-4, and IDO1 coordinately induces immune-mediated liver injury in mice by Affolter, Timothy, Llewellyn, Heather P, Bartlett, Derek W, Zong, Qing, Xia, Shuhua, Torti, Vince, Ji, Changhua

“…Cancer cells harness immune checkpoints such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1) and indoleamine…”
Get full text

Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging by Bartlett, Derek W, Su, Helen, Hildebrandt, Isabel J, Weber, Wolfgang A, Davis, Mark E

“…Targeted delivery represents a promising approach for the development of safer and more effective therapeutics for oncology applications. Although…”
Get full text

Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles by Bartlett, Derek W, Davis, Mark E

“…This study addresses issues of relevance for siRNA nanoparticle delivery by investigating the functional impact of tumor-specific targeting and dosing…”
Get full text

Physicochemical and Biological Characterization of Targeted, Nucleic Acid-Containing Nanoparticles by Bartlett, Derek W, Davis, Mark E

“…Nucleic acid-based therapeutics have the potential to provide potent and highly specific treatments for a variety of human ailments. However, systemic delivery…”
Get full text

Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma by HU-LIESKOVAN, Siwen, HEIDEL, Jeremy D, BARTLETT, Derek W, DAVIS, Mark E, TRICHE, Timothy J

“…The development of effective, systemic therapies for metastatic cancer is highly desired. We show here that the systemic delivery of sequence-specific small…”
Get full text

Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA-mediated gene silencing by Bartlett, Derek W, Davis, Mark E

“…Small interfering RNA (siRNA) molecules achieve sequence-specific gene silencing through the RNA interference (RNAi) mechanism. Here, live-cell and live-animal…”
Get full text

A Microfluidic Perfusion Platform for In Vitro Analysis of Drug Pharmacokinetic-Pharmacodynamic (PK-PD) Relationships by Guerrero, Yadir A., Desai, Diti, Sullivan, Connor, Kindt, Erick, Spilker, Mary E., Maurer, Tristan S., Solomon, Deepak E., Bartlett, Derek W.

“…Static in vitro cell culture studies cannot capture the dynamic concentration profiles of drugs, nutrients, and other factors that cells experience in…”
Get full text

Preclinical Efficacy of the Camptothecin-Polymer Conjugate IT-101 in Multiple Cancer Models by SCHLUEP, Thomas, HWANG, Jungyeong, JIANJUN CHENG, HEIDEL, Jeremy D, BARTLETT, Derek W, HOLLISTER, Beth, DAVIS, Mark E

“…Preclinical efficacy of i.v. IT-101, a nanoparticulate conjugate of 20( S )-camptothecin and a cyclodextrin-based polymer, was investigated in several mouse…”
Get full text

Potent siRNA Inhibitors of Ribonucleotide Reductase Subunit RRM2 Reduce Cell Proliferation In vitro and In vivo by HEIDEL, Jeremy D, LIU, Joanna Yi-Ching, YUN YEN, BINGSEN ZHOU, HEALE, Bret S. E, ROSSI, John J, BARTLETT, Derek W, DAVIS, Mark E

“…Purpose: Ribonucleotide reductase (RR) is a therapeutic target for DNA replication–dependent diseases such as cancer. Here, a potent small interfering RNA…”
Get full text

Translational PK-PD for targeted protein degradation by Bartlett, Derek W, Gilbert, Adam M

“…Targeted protein degradation has emerged from the chemical biology toolbox as one of the most exciting areas for novel therapeutic development across the…”
Get more information

Delivering on the promise of protein degraders by O’Brien Laramy, Matthew N., Luthra, Suman, Brown, Matthew F., Bartlett, Derek W.

“…Over the past 3 years, the first bivalent protein degraders intentionally designed for targeted protein degradation (TPD) have advanced to clinical trials,…”
Get full text

A kinetic proofreading model for bispecific protein degraders by Bartlett, Derek W., Gilbert, Adam M.

“…Bispecific protein degraders (BPDs) engage the ubiquitin–proteasome system (UPS) to catalytically degrade intracellular proteins through the formation of…”
Get full text

Increasing dialysate flow and dialyzer mass transfer area coefficient to increase the clearance of protein-bound solutes by MEYER, Timothy W, LEEPER, Evonne C, BARTLETT, Derek W, DEPNER, Thomas A, YIMING ZHAO LIT, ROBERTSON, Channing R, HOSTETTER, Thomas H

“…Clinical hemodialysis systems achieve high single pass extraction of small solutes that are not bound to plasma proteins. But they clear protein-bound solutes…”
Get full text

A Quantitative Systems Pharmacology Platform to Investigate the Impact of Alirocumab and Cholesterol-Lowering Therapies on Lipid Profiles and Plaque Characteristics by Ming, Jeffrey E, Abrams, Ruth E, Bartlett, Derek W, Tao, Mengdi, Nguyen, Tu, Surks, Howard, Kudrycki, Katherine, Kadambi, Ananth, Friedrich, Christina M, Djebli, Nassim, Goebel, Britta, Koszycki, Alex, Varshnaya, Meera, Elassal, Joseph, Banerjee, Poulabi, Sasiela, William J, Reed, Michael J, Barrett, Jeffrey S, Azer, Karim

“…Reduction in low-density lipoprotein cholesterol (LDL-C) is associated with decreased risk for cardiovascular disease. Alirocumab, an antibody to proprotein…”
Get full text

Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging by Bartlett, Derek W., Davis, Mark E.

“…Small interfering RNA (siRNA) molecules are potent effectors of post-transcriptional gene silencing. Using noninvasive bioluminescent imaging and a…”
Get full text

Noninvasive Imaging of PSMA in prostate tumors with (89)Zr-Labeled huJ591 engineered antibody fragments: the faster alternatives by Viola-Villegas, Nerissa Therese, Sevak, Kuntal K, Carlin, Sean D, Doran, Michael G, Evans, Henry W, Bartlett, Derek W, Wu, Anna M, Lewis, Jason S

“…Engineered antibody fragments offer faster delivery with retained tumor specificity and rapid clearance from nontumor tissues. Here, we demonstrate that…”
Get full text

Activatable fluorescent cys-diabody conjugated with indocyanine green derivative: consideration of fluorescent catabolite kinetics on molecular imaging by Sano, Kohei, Nakajima, Takahito, Ali, Towhid, Bartlett, Derek W, Wu, Anna M, Kim, Insook, Paik, Chang H, Choyke, Peter L, Kobayashi, Hisataka

“…Antibody fragments including diabodies have more desirable pharmacokinetic characteristics than whole antibodies. An activatable optical imaging probe based on…”
Get full text

Noninvasive Imaging of PSMA in Prostate Tumors with 89Zr-Labeled huJ591 Engineered Antibody Fragments: The Faster Alternatives by Viola-Villegas, Nerissa Therese, Sevak, Kuntal K, Carlin, Sean D, Doran, Michael G, Evans, Henry W, Bartlett, Derek W, Wu, Anna M, Lewis, Jason S

“…Engineered antibody fragments offer faster delivery with retained tumor specificity and rapid clearance from nontumor tissues. Here, we demonstrate that…”
Get full text

Rapid and Efficient Production of Radiolabeled Antibody Conjugates Using Vacuum Diafiltration Guided by Mathematical Modeling by Bartlett, Derek W, Colcher, David, Raubitschek, Andrew A

“…Increasing interest in the use of radiolabeled antibodies for cancer imaging and therapy drives the need for more efficient production of the antibody…”
Get full text

705. A Practical Approach to siRNA-Based Treatment Design Using Bioluminescent Imaging and Mathematical Modeling by Bartlett, Derek W., Davis, Mark E.

“…Small interfering RNA (siRNA) molecules achieve sequence-specific gene silencing through a process known as RNA interference (RNAi). Compared to other nucleic…”
Get full text